Pharmacokinetics of UGN‑102, an investigational mitomycin‑containing reverse thermal gel for the treatment of non-muscle invasive bladder cancer
Cancer Chemotherapy and Pharmacology · 2025
DOI: 10.1007/s00280-025-04821-5 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Sandip M Prasad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Morristown Medical Center/Atlantic Health System and Garden State Urology, Morristown, NJ, USA. Sandip.Prasad@atlantichealth.org. Hauptthemen laut MEDLINE: Antibiotics, Antineoplastic, Mitomycin, Mitomycins, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: UroGen Pharma.
Abstract (Originalsprache)
PURPOSE: To evaluate the pharmacokinetic properties of UGN-102, a mitomycin-containing reverse thermal gel. METHODS: Twelve patients with NMIBC received 6 once-weekly intravesical instillations of UGN-102 (BL004: 120 mg mitomycin [n = 6]; BL005: 75 mg mitomycin [n = 6]). Plasma samples for determination of pharmacokinetic (PK) parameters were collected up to 6 h following instillation. RESULTS: In BL004, mean Cmax was 20.39 ng/mL, and median was 16.10 ng/mL (range 4.00-40.40), 100-10-fold lower than reported myelosuppression toxic level (RMTL); and median Tmax was 1.5 h. Mean AUC0-6 was 56.23 ng·h/mL and mean apparent terminal half-life (t1/2) was 49 min. The highest observed Cmax (40.40 ng/mL) was 59-fold and 13-fold lower than Cmax following IV 30 mg or 10 mg mitomycin, respectively, and 10-fold lower than the RMTL. Maximum measured urine concentration was 635 µg/mL. In BL005, mean Cmax was 2.27 ng/mL, 181-fold lower than the RMTL; mean Tmax was 1.95 h and mean AUC0-6 was 5.69 ng·h/mL. At 4-6 h post intravesical instillation, mitomycin concentrations in urine were either below or approaching the lower level of quantification ( 6 h post-instillation, possibly due to the tumor location restricting urine flow. However systemic exposure was < 4 ng/mL, 100-fold lower than the RMTL. CONCLUSIONS: Intravesical instillation of UGN-102 results in low-level systemic absorption of mitomycin, with Cmax values considerably lower than those following IV administration and those associated with myelosuppression. STUDY REGISTRATION: BL004: NCT02307487; BL005: NCT03558503.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Morristown Medical Center/Atlantic Health System and Garden State Urology, Morristown, NJ, USA. Sandip.Prasad@atlantichealth.org.
- UroGen Pharma, Princeton, NJ, USA.
Förderung
- UroGen Pharma
Zitieren
APA
Prasad, S. M., Louie, M. J., Burger, B., Tsurutis, V., Ugwuoke, N., & Strauss-Ayali, D. (2025). Pharmacokinetics of UGN‑102, an investigational mitomycin‑containing reverse thermal gel for the treatment of non-muscle invasive bladder cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04821-5
Vancouver
Prasad SM, Louie MJ, Burger B, Tsurutis V, Ugwuoke N, Strauss-Ayali D. Pharmacokinetics of UGN‑102, an investigational mitomycin‑containing reverse thermal gel for the treatment of non-muscle invasive bladder cancer. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04821-5
BibTeX
@article{Prasad2025,
author = {Prasad, Sandip M and Louie, Michael J and Burger, Brent and Tsurutis, Victoria and Ugwuoke, Nikky and Strauss-Ayali, Dalit},
title = {Pharmacokinetics of UGN‑102, an investigational mitomycin‑containing reverse thermal gel for the treatment of non-muscle invasive bladder cancer},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2025},
doi = {10.1007/s00280-025-04821-5}
}
EUVIMED